Clinical trials: Carboplatin, open to volunteers
Lung Cancer, Extensive-stage Small-cell Lung Cancer
Durvalumab Combined With Consolidation Radiotherapy After First-line Treatment in Extensive Stage Small Cell Lung Cancer With Oligometastases
In patients with oligometastatic (1-5 lesions) extensive-stage small cell lung cancer, to explore the efficacy and safety of Durvalumab immunotherapy combined with chemotherapy followed by consolidation radiotherapy, to provide…
- Conditions
- Lung Cancer, Extensive-stage Small-cell Lung Cancer, Radiotherapy
- Trial name
- NCT05484583
- Testing
- Durvalumab + carboplatin/cisplatin + etoposide, Consolidation radiotherapy, Durvalumab
- Volunteers
- 58 people
- Sponsor
- Affiliated Cancer Hospital & Institute of Guangzhou Medical University
Small Cell Lung Carcinoma
Maintenance Durvalumab (MEDI4736) and Olaparib (AZD2281) After Standard 1st Line Treatment (Carboplatin/Cisplatin, Etoposide, Durvalumab) in HRD Positive Extensive Disease (ED) Small-cell Lung Cancer (SCLC)
Maintenance durvalumab (MEDI4736) and olaparib (AZD2281) after standard 1st line treatment (carboplatin/ cisplatin, etoposide, durvalumab) in HRD positive extensive disease (ED) small-cell lung cancer (SCLC)
- Trial name
- GUIDANCE (NCT06419179)
- Testing
- Durvalumab, Olaparib
- Where
- Germany
- Volunteers
- 29 people
- Sponsor
- University of Cologne
EGFR, NSCLC (Advanced Non-small Cell Lung Cancer)
Firmonertinib Versus Platinum Based Chemotherapy as First-line Treatment for NSCLC With EGFR PACC or EGFR l861q Mutation
This study is a randomized, open, multicenter phase III clinical study, which aims to evaluate the efficacy and safety of firmonertinib mesylate compared with platinum based chemotherapy for patients with locally advanced or…
- Trial name
- NCT06956001
- Testing
- Firmonertinib Mesilate Tablets, Pemetrexed Disodium for Injection, Cisplatin for injection
- Where
- 2 sites in China
- Volunteers
- 300 people
- Sponsor
- Allist Pharmaceuticals, Inc.
Small Cell Lung Cancer
Liposomal Irinotecan Combination Regimen for First-line Treatment of Small Cell Lung Cancer
Lung cancer is a malignant tumor with high incidence and mortality in China and the world, among which small cell lung cancer (SCLC) accounts for 13% to 17% of lung cancer, and about 250,000 patients are diagnosed with SCLC every…
- Trial name
- NCT06462105
- Testing
- Irinotecan Hydrochloride Liposome Injection；Carboplatin Injection；Serplulimab Injection
- Volunteers
- 60 people
- Sponsor
- Zhou Chengzhi
Head and Neck Squamous Cell Carcinoma (HNSCC) - Recurrent/Metastatic (R/M)
A Clinical Trial Comparing the Efficacy and Safety of Anyouping® and Platinum-based Chemotherapy With or Without Enlituo® in Advanced Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma.
A Clinical Trial Comparing the Efficacy and Safety of Anyouping® and Platinum-based Chemotherapy With Enlituo® in Advanced Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma.
- Trial name
- NCT07791745
- Testing
- Enlituo® + Anyouping® + PBC
- Where
- China
- Volunteers
- 362 people
- Sponsor
- Taizhou Mabtech Pharmaceutical Co.,Ltd
Esophageal Squamous Cell Carcinoma (ESCC)
Neoadjuvant Chemoradiotherapy Versus Neoadjuvant Immunochemotherapy for Resectable Esophageal Cancer: A Target Trial Emulation Study
Esophageal squamous cell carcinoma (ESCC) is highly prevalent in China, with most patients presenting with locally advanced disease.
- Trial name
- TTE-ESCC (NCT07778056)
- Testing
- Radiotherapy, Platinum-based Chemotherapy, PD-1 Inhibitor
- Volunteers
- 400 people
- Sponsor
- Henan Cancer Hospital
Ototoxicity, Drug-Induced
Diagnostic of Various Ototoxicity Induced by Cancer Treatment
Visit the clinic once every 2 weeks for checkups and tests The goal of this clinical trial is to learn if systematic hearing tests (eg fonctional assesment, electrophysiology and seric biomarkers) can diagnose hidden hearing loss…
- Trial name
- BIO-OTOTOX (NCT06490029)
- Testing
- Auditory, vestibular and electrophysiological investigations, Biologic investigations; seric proteins
- Where
- France
- Volunteers
- 540 people, healthy volunteers welcome
- Sponsor
- Direction Centrale du Service de Santé des Armées
Recurrent/Metastatic Endometrial Cancer
Adebrelimab Plus Carboplatin/Paclitaxel Followed by Adebelizumab with or Without Apatinib in the Treatment of Advanced Recurrent/Metastatic Endometrial Cancer (A-CAPE): a Multicenter, Randomized, Controlled, Open-Label Clinical Trial
This study takes investigator-assessed Progression-Free Survival (PFS) as the primary endpoint, with plans to enroll 140 patients with advanced recurrent/metastatic endometrial cancer in a 1:1 ratio, randomized into an…
- Trial name
- A-CAPE (NCT06771154)
- Testing
- Adebelimab Combined with Apatinib, Adebelimab
- Where
- China
- Volunteers
- 140 people
- Sponsor
- Peking Union Medical College Hospital
Breast Neoplasm Female
A Prospective, Open, Multicenter Single-arm Clinical Studie of Docetaxel, Carboplatin Combined With Inetetamab and Pyrotinib in the Treatment of Local-advanced HER2-positive Breast Cancer
This study is a prospective, open, multi-center, single arm trial. The treatment group will receive six cycles of docetaxel, carboplatin combined with Inetetamab and Pyrotinib before surgery.
- Trial name
- neoPICD (NCT06234137)
- Testing
- Docetaxel, Carboplatin, Inetetamab
- Where
- China
- Volunteers
- 154 people
- Sponsor
- Wang Ouchen
Non Small Cell Lung Cancer, Stage IIIA Lung Cancer
Neoadjuvant Treatment With Atezolizumab and Atezolizumab as Maintenance for the Treatment of Stage III Non Small-Cell Lung Cancer (NSCLC)
This is an open-label, phase II, multi-centre clinical trial. 97 Patients with stage IIIA and IIIB non-small cell lung cancer will be enrolled.
- Conditions
- Non Small Cell Lung Cancer, Stage IIIA Lung Cancer, Stage IIIB Lung Cancer
- Trial name
- ATHENEA (NCT07153445)
- Testing
- Atezolizumab, Paclitaxel, Carboplatin
- Where
- 21 sites in Spain
- Volunteers
- 97 people
- Sponsor
- Fundación GECP
Cervix Cancer, Cadonilimab
Evaluation of AK104 (Cadonilimab) Combined with Chemotherapy for Recurrent or Metastatic Small Cell Neuroendocrine Carcinoma of the Cervix
The goal of this clinical trial is to evaluate the safety and effectiveness of AK104 (Cadonilimab) combined with chemotherapy (cisplatin or carboplatin, and etoposide) for the treatment of recurrent or metastatic small cell…
- Conditions
- Cervix Cancer, Cadonilimab, Small Cell Neuroendocrine Carcinoma of the Cervix
- Trial name
- NCT06810895
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Ding Ma
HER2-positive Early-stage Breast Cancer
Optimize Neoadjuvant Therapy in HER2-Positive Early-Stage Breast Cancer
This is an open-label phase 2 study to evaluate the pCR rate in patients diagnosed with HER2 positive breast cancer treated on an adaptive clinical trial design.
- Trial name
- EUREKA (NCT07402473)
- Testing
- Trastuzumab, Pertuzumab, Docetaxel
- Where
- 7 sites in United States
- Volunteers
- 50 people
- Sponsor
- Rutgers, The State University of New Jersey
Carcinoma, Non-Small-Cell Lung
A Study of Neoadjuvant Amivantamab With Either Lazertinib or Chemotherapy in Participants With Resectable EGFR-Mutated NSCLC
The purpose of this study is to assess the ability to slow down or stop the growth of cancer with amivantamab combined with either lazertinib or chemotherapy (carboplatin and pemetrexed) in participants with resectable, epidermal…
- Trial name
- AmiNA (NCT07586202)
- Testing
- Amivantamab, Lazertinib, Carboplatin
- Where
- 27 sites in United States, Canada and 4 more
- Volunteers
- 68 people
- Sponsor
- Janssen Research & Development, LLC
Large Cell Neuroendocrine Carcinoma of the Lung
FIRST-NEC (GFPC 01-2022) - Combination of Durvalumab With Etoposide and Platinum
The primary objective is to determine the efficacy (Progression-Free Rate at 12 months) of durvalumab combined with etoposide and platinum (either cisplatin or carboplatin) for the first-line treatment of patients with advanced…
- Trial name
- FIRST-NEC (NCT06393816)
- Testing
- Durvalumab with etoposide and Carboplatin/Cisplatin
- Where
- 31 sites in France, Reunion
- Volunteers
- 80 people
- Sponsor
- Centre Leon Berard
Solid Tumor, Non-Small Cell Lung Cancer
Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)
This is a Phase 1/2, open-label, non-randomized, 4-part trial to determine the safety profile and identify the maximum tolerated dose (MTD) and/or recommended Phase 2 dose (RP2D) of INBRX 106 administered as a single agent or in…
- Conditions
- Solid Tumor, Non-Small Cell Lung Cancer, Head and Neck Cancer, Melanoma
- Trial name
- NCT04198766
- Testing
- INBRX-106 - Hexavalent OX40 agonist antibody, pembrolizumab 200 mg, pembrolizumab 400 mg
- Where
- 60 sites in United States, Singapore and 2 more
- Volunteers
- 340 people
- Sponsor
- Inhibrx Biosciences, Inc
Breast Cancer
Pyrotinib Combined With Trastuzumab, Dalpiciclib, Letrozole Versus TCbHP (Trastuzumab Plus Pertuzumab With Docetaxel and Carboplatin) as Neoadjuvant Treatment in HR +/HER2 + Breast Cancer
This is an investigator-initiated randomized controlled, open-label, multicenter, prospective Phase 2 clinical study. Patients with stage II-III HR +/HER2 + breast cancer were randomly divided into two groups at a ratio of 1:1.
- Trial name
- NCT05638594
- Testing
- Pyrotinib, Trastuzumab, Dalpiciclib
- Where
- China
- Volunteers
- 236 people
- Sponsor
- Shengjing Hospital
Malignant Pleural Mesothelioma, Advanced
Efficacy and Safety of Ivonescimab Plus Pemetrexed and Platinum-Based Chemotherapy in Advanced Malignant Pleural Mesothelioma
This Phase 1b/2, open-label, multicenter, single-arm study evaluates the safety and efficacy of ivonescimab in combination with pemetrexed and platinum-based chemotherapy as first-line treatment for advanced malignant pleural…
- Trial name
- NCT07885319
- Testing
- Ivonescimab Combined With Chemotherapy
- Where
- 3 sites in China
- Volunteers
- 78 people
- Sponsor
- Ruijin Hospital
LA HNSCC
Cetuximab + Tislelizumab + Chemotherapy in the Treatment of Unresectable LA HNSCC
This prospective, single-arm, Phase II study aims to evaluate the efficacy, safety, and surgical conversion rate of Cetuximab combined with Tislelizumab and chemotherapy for unresectable LA HNSCC.
- Trial name
- NCT06978829
- Testing
- TP + Cetuximab + Tislelizumab
- Where
- China
- Volunteers
- 42 people
- Sponsor
- Daping Hospital and the Research Institute of Surgery of the Third Military Medical University
Sub-study 1 Cervical Cancer (Volrustomig Monotherapy), Sub-study 2 Head and Neck Squamous Cell Carcinoma (Volrustomig Monotherapy)
Study of Volrustomig as Monotherapy or in Combination With Anti- Cancer Agents in Participants With Advanced/Metastatic Solid Tumors
eVOLVE-02 study will evaluate the efficacy and safety of volrustomig as monotherapy or in combination with anti-cancer agents in participants with advanced/metastatic solid tumors.
- Conditions
- Sub-study 1 Cervical Cancer (Volrustomig Monotherapy), Sub-study 2 Head and Neck Squamous Cell Carcinoma (Volrustomig Monotherapy), Sub-study 3 Head and Neck Squamous Cell Carcinoma (Volrustomig in Combination With Chemotherapy), Sub-study 4 Esophageal Squamous Cell Carcinoma (Volrustomig in Combination With Chemotherapy)
- Trial name
- eVOLVE-02 (NCT06535607)
- Testing
- Volrustomig, Cisplatin, Carboplatin
- Where
- 98 sites in United States, Australia and 10 more
- Volunteers
- 257 people
- Sponsor
- AstraZeneca
Epithelial Ovarian Carcinoma Stage III, Epithelial Ovarian Carcinoma Stage IV
Nab-paclitaxel Versus Sb-taxanes As First-Line Treatment in Advanced Ovarian Cancer
The purpose of this study is to compare the efficacy and safety of nab-paclitaxel with solvent-based taxanes as first-line treatment for patients with advanced primary epithelial ovarian cancer (EOC), primary peritoneal carcinoma…
- Conditions
- Epithelial Ovarian Carcinoma Stage III, Epithelial Ovarian Carcinoma Stage IV, Fallopian Tube Carcinoma Stage III, Fallopian Tube Carcinoma Stage IV
- Trial name
- NCT05737303
- Testing
- nab-paclitaxel combined with carboplatin
- Where
- 11 sites in China
- Volunteers
- 538 people
- Sponsor
- Women's Hospital School Of Medicine Zhejiang University
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.